News
Novo Nordisk: Is the Ozempic Hype Train Finally Slowing Down?
Yesterday, we reported that Novo Nordisk (NYSE: NVO) stock crashed over 20% in premarket trading yesterday. The main culprit is the reduced sales forecast for the company’s flagship obesity drug Wegovy, going down from May’s 21% growth projection to just a 14% sales increase throughout 2025.
Novo Nordisk stock plunges 30% after forecast cut, CEO shakeup, and rising competition hit investor confidence.
Shares of Novo Nordisk ( NVO 2.48%) are falling this week, down 33% as of 3:27 p.m. ET on Friday. The drop comes as the S&P ...
Novo Nordisk faces slowing demand, rising competition, and CEO transition. Learn about challenges impacting its growth and ...
U.S.-listed shares of Novo Nordisk (NVO) sank roughly 20% in premarket trading after the Danish drugmaker cut its full-year ...
Ozempic-maker Novo Nordisk and the FDA are testing the seized products, according to the notice. The illegitimate products come with pen labels, cartons, fact sheets and needles that are also ...
Novo Nordisk’s Wegovy is FDA-approved for weight loss, while its lower-dose GLP-1 cousin Ozempic is only officially approved for Type 2 diabetes but is often prescribed off-label for weight loss ...
The soaring popularity of weight loss drugs Ozempic and Wegovy has catapulted parent company Novo Nordisk’s valuation past the half-trillion dollar threshold, according to a report. The Danish ...
Furious competition in GLP-1 drugs rebuts the anti-pharma crowd.
A five-year experiment aims to open access to blockbuster GLP‑1 drugs for obesity, something advocates have pushed for years.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback